OPK vs GBX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
OPK · Opko Health$1.73 ▼ 1.14%
GBX · Greenbrier Companies$41.51 ▼ 3.20%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- OPK +30.1%
- GBX -1.0%
Head to head
| Metric | OPK | GBX |
|---|---|---|
| Price | $1.73 | $41.51 |
| Change today | ▼ 1.14% | ▼ 3.20% |
| Market cap | $1.28B | $1.29B |
| Return, 3 months | +24.5% | -10.0% |
| Return, year to date | +37.3% | -9.4% |
| Return, 1 year | +29.1% | -0.9% |
| P/E (TTM) | -8.7 | 16.7 |
| P/B | 1.2 | 0.8 |
| P/E percentile vs own 5y | 5th | 57th |
| Dividend yield | – | 3.18% |
| Revenue growth (YoY, latest qtr) | +4.3% | -22.2% |
| Net profit growth (YoY) | +94.3% | -68.0% |
| Gross margin | 40.8% | 13.6% |
| Operating margin | -28.6% | 4.3% |
| Net margin | -12.4% | 3.2% |
| Return on equity | -5.9% | 5.1% |
| Analyst target vs. price | +78.0% | -8.5% |
| Analyst buy share | 100% | 0% |
| RSI (14) | 62 | 55 |
| 30-day volatility | 65.3% | 39.7% |
| Max drawdown, 1 year | -24.7% | -35.4% |
| Trend read | Strong uptrend | Leaning bullish |
| Analyst consensus | Buy | Sell |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- GBX is the largest of the group by market value.
- OPK has returned the most over the past year.
- OPK carries the lowest trailing P/E.
- OPK is growing revenue fastest.
- GBX keeps the most profit per dollar of sales.
- GBX has been the calmest stock over the last 30 days.